Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Neuroblastoma 1Lymphoma, Mantle-Cell 1Leukemia, Promyelocytic, Acute 1Leukemia, Prolymphocytic, T-Cell 1Leukemia 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Breast Neoplasms 1Amyloidosis 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Lisaftoclax × Clear all
NCT04946864 2024-08-19

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Ascentage Pharma Group Inc.

Phase 1/2 Suspended
65 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡